Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive blood cancer that impacts lymphocytes, a type of white blood cell vital to your immune system. RITUXAN HYCELA® is administered as a subcutaneous injection under the skin during scheduled visits with your healthcare provider. Treatment begins with an initial dosing schedule, and infusions are tailored to your specific health needs. Your healthcare provider will help guide you through preparing for treatment and provide insights into safety considerations to monitor potential risks during therapy.
Common side effects of RITUXAN HYCELA include infusion-related reactions, fatigue, and nausea. Rare but serious side effects may occur, and it’s important that your healthcare provider monitors you closely throughout treatment. Discover more about the goals of treatment and how RITUXAN HYCELA may work for you.
For additional support on your journey, access helpful resources such as questions to ask your doctor, financial assistance options, or get advice from a dedicated case manager.
The BrandX™ Co-pay Card Program may help lower the out-of-pocket costs for your patients.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.